Summit Therapeu ADR
(NQ:
SMMT
)
22.70
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeu ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Summit Therapeutics Raises $235 Million
Today 6:30 EDT
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
September 11, 2024
Via
Benzinga
Is Summit Therapeutics a Buy Now?
September 10, 2024
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.
Via
The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
September 09, 2024
Via
Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
September 09, 2024
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.
Via
Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
September 09, 2024
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
September 08, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024
August 06, 2024
SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
August 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
July 29, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
July 26, 2024
Via
Benzinga
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
July 25, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
July 23, 2024
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?
Via
Investor's Business Daily
Topics
Government
Exposures
Political
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
July 22, 2024
Via
Benzinga
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
7 Top Stocks Under $10: June 2024 Edition
June 24, 2024
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.
Via
InvestorPlace
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
June 17, 2024
These high-flying stocks could have more room to run if analysts are right.
Via
The Motley Fool
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
June 07, 2024
Via
Benzinga
Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 06, 2024
Via
Benzinga
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
June 03, 2024
Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
June 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.